Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System

Inclusion criteria

• Fitzpatrick Skin Type I-VI and Wrinkle Class I
• Between the ages of 25-65
• Evidence of bilateral dyschromia

Exclusion criteria

• Pregnant, lactating, or is planning to become pregnant
• history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis
• any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical or systemic therapy
• coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
• any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study
• currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days
• unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
• unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
• Accutane within 6 months
• need to be exposed to artificial tanning devices or excessive sunlight during the trial
• prior treatment with parenteral gold therapy
• Diabetes Type 1 or 2
• does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study
• artificial tanning within 1 month
• (micro)dermabrasion within 3 months
• other laser or IPL to the face within 6 months
• chemical peel within 1 month
• injectable fillers within 3 months
• topical retinoids within 3 months
• over-the-counter anti-aging products (e.g., those containing peptides, hyaluronic acid, or agents specifically advertised as having anti-aging or age-inhibiting properties) within 1 month
• history of keloids or hypertrophic scarring
• evidence of compromised wound healing
• history of cold sores, chickenpox or shingles and unwilling to take a prophylactic course of Valtrex/acyclovir
• allergy to acyclovir